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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.10.045Objectives: We sought to evaluate the efficacy of recombinant human antithrombin
III for restoration of heparin responsiveness in heparin-resistant patients scheduled
for cardiac surgery.
Methods: This was a multicenter, randomized, double-blind, placebo-controlled
study in heparin-resistant patients undergoing elective cardiac surgery. Patients
were considered heparin resistant if the activated clotting time was less than 480
seconds after 400 U/kg heparin. Fifty-two heparin-resistant patients were random-
ized into 2 cohorts. One cohort received a single bolus (75 U/kg) of recombinant
human antithrombin III (n  28), and the other, the placebo group (n  24),
received a normal saline bolus. If the activated clotting time remained less than 480
seconds, this was defined as treatment failure, and 2 units of fresh frozen plasma
were transfused. Patients were monitored for adverse events during hospitalization.
Results: Six (21%) of the patients in the recombinant human antithrombin III group
received fresh frozen plasma transfusions compared with 22 (92%) of the placebo-
treated patients (P .001). Two units of fresh frozen plasma did not restore heparin
responsiveness. There was no increased incidence of adverse events associated with
recombinant human antithrombin III administration. Postoperative 24-hour chest
tube bleeding was not different in the 2 groups. Surrogate measures of hemostatic
activation suggested that there was less activation of the hemostatic system during
cardiopulmonary bypass in the recombinant human antithrombin III group.
Conclusion: Treatment with recombinant human antithrombin III in a dose of 75
U/kg is effective in restoring heparin responsiveness and promoting therapeutic
anticoagulation for cardiopulmonary bypass in the majority of heparin-resistant
patients. Two units of fresh frozen plasma were insufficient to restore heparin
responsiveness. There was no apparent increase in bleeding associated with recom-
binant human antithrombin III.
Effective anticoagulation is a prerequisite for the safe institution of cardio-pulmonary bypass (CPB). By inducing a conformational change in theantithrombin III (ATIII) tertiary structure, unfractionated heparin increases
the affinity of ATIII for thrombin approximately 1000-fold. ATIII is a naturally
occurring plasma protein that inhibits thrombin and factor Xa (and other circulating
coagulation factors) and binds to heparan sulfate moieties on the vascular endothe-
lium to help maintain homeostasis of the hemostatic system. Heparin’s anticoagu-
lant effect is closely tied to ATIII activity. Accordingly, abnormally low ATIII
plasma activity might lead to an altered anticoagulant response to heparin. During
CPB, therapeutic anticoagulation is usually monitored by the activated clotting time
(ACT), a simple and rapid point-of-care test. The decision to initiate CPB after
heparin administration hinges on attaining an adequate ACT. Limited data exist that
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CSPdefine the optimal ACT for initiation of CPB,1 but histori-
cally, values of less than 300 seconds were associated with
grossly visible clots in the bypass circuit. In a 1000-member
survey of the Society of Cardiovascular Anesthesiology and
American Society of Extracorporeal Circulation, the target
ACT used by 82% of responders was 400 to 480 seconds or
longer, with an additional 4.5% targeting an even higher
ACT.2
Heparin resistance can be defined as the failure to
achieve the desired ACT after a standard dose of heparin
(300-400 U/kg).2 Failure to achieve an acceptable ACT for
CPB is usually managed by additional heparin administra-
tion. Less frequently, fresh frozen plasma (FFP) is admin-
istered in an attempt to restore heparin responsiveness.
Investigators have found the incidence of heparin resistance
among patients undergoing cardiac surgery to vary between
4% and 13%, depending on the target ACT and heparin dose
required and on whether patients have recently received
heparin.3,4
Lower ATIII levels are associated with a decreased
heparin dose response (HDR), as measured by the ACT.5
ATIII supplementation has been used to improve the
ACT response to heparin6 and is associated with better
thrombin inhibition.5 Initial studies suggest that recom-
binant human ATIII (rhATIII) is effective in restoring
heparin responsiveness in patients with heparin resis-
tance.7 A previous study established that single dosing
with 75 U/kg or more of rhATIII resulted in plasma ATIII
levels approximating 100% activity that were maintained
throughout CPB.7
FFP is readily available at most institutions and has
been effectively used as an exogenous source of ATIII to
restore heparin responsiveness.8 FFP as a source of ATIII
is one of the medically accepted treatments for heparin
resistance. FFP, however, is not an innocuous interven-
tion and carries the risk of several complications, includ-
ing viral infections and allergic reactions. It is also pos-
sible that FFP increases ATIII concentrations only when
large volumes (2 L) are administered. The current study
was therefore designed to assess the efficacy and safety
of rhATIII for improving heparin responsiveness in he-
parin-resistant patients undergoing elective cardiac sur-
gery involving CPB, thereby avoiding the need for FFP.
The trial also aimed to assess whether rhATIII at a dose
of 75 U/kg increases plasma ATIII activity and inhibits
thrombin and fibrinolytic activity more effectively than 2
units of FFP.
Methods
Review and written approval of the study protocol by the inde-
pendent ethics committees or institutional review boards was ob-
tained before initiation of each study site. Written informed con-
sent was obtained from each enrolled participant.
108 The Journal of Thoracic and Cardiovascular Surgery ● JulyStudy Design
This multicenter, randomized, double-blind, placebo-controlled
rhATIII efficacy study included patients at 6 European study
centers undergoing first-time elective coronary artery bypass sur-
gery requiring CPB. This population was chosen because FFP is
sometimes administered as a source of ATIII to facilitate heparin
anticoagulation in heparin-resistant patients before or during
CPB.8
Patients 18 to 85 years of age scheduled for elective cardiac
surgery and requiring CPB were included in the study. No patients
received aprotinin or any other antifibrinolytic agent. The bypass
circuits were not heparin coated, systems were open, cardiotomy
suction was used, and patients were cooled to 32°C. Patients who
had a baseline HDR slope of 80 seconds or less with the Hepcon
Hemostasis Management System (Medtronics, Minneapolis,
Minn) were eligible. In addition, patients who had received intra-
venous heparin before surgical intervention, regardless of the HDR
slope, were also eligible. Patients were excluded who had recently
received or were receiving one or more of the following medica-
tions: warfarin (within 3 days); streptokinase; tissue plasminogen
activator; abciximab, eptifibatide, or tirofiban; or clopidogrel. Also
excluded were patients with preexisting coagulopathy defined as a
history of bleeding problems or a laboratory history of a bleeding
disorder.
Patients were considered heparin resistant if their ACT was less
than 480 seconds (ACT II, Medtronics) 5 minutes after receiving
a heparin dose of 300 U/kg, followed by an additional 100 U/kg
(total heparin dose, 400 U/kg). Heparin-resistant patients were
randomized into one of the 2 treatment groups. One group received
a single-bolus 75 U/kg intravenous injection of rhATIII, and the
other received a single-bolus intravenous injection of a normal
saline placebo. If after the randomized bolus the ACT remained
less than 480 seconds, this was defined as treatment failure, and 2
units of FFP were transfused. Additional heparin was administered
during CPB as guided by the automated protamine titration method
(Hepcon, Medtronics) and ACT values. Reversal of heparin with
protamine after CPB was per institutional protocol.
Blood for measurement of hematologic parameters was ob-
tained just before study drug administration (0 minutes), at 30
minutes after the initiation of CPB, and just before heparin reversal
with protamine. These parameters included Kaolin ACT without
heparinase and plasma ATIII activity levels. The ACT II (Auto-
mated Coagulation Timer, Medtronics) device was used for mea-
suring the ACT during the treatment period. ACTrac (Medtronics),
an electronic calibration device, was used in conjunction with the
ACT II device to insure that evaluation values by using Hepcon
(Medtronics), and study values with ACT II were consistent be-
tween the 2 devices. Additional blood was obtained at baseline and
4 weeks postoperatively to monitor serum samples for antibody
formation to rhATIII.
All adverse events occurring from the time of study drug
administration until hospital discharge and during the 4-week
postoperative follow-up period were recorded. Blood and blood
components transfused in the perioperative period were recorded.
Postoperative blood loss through chest tube drainage was also
recorded. Four weeks postoperatively, a blood sample for rhATIII
was obtained, and a postoperative review for serious adverse
events was performed.
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PThe study’s primary efficacy end point was whether rhATIII
restores heparin responsiveness. Patients who met the requirement
for FFP but did not receive FFP were included in the analysis of
patients who received FFP (ie, intention to treat). Secondary end
points were comparisons between study groups of ACT values and
plasma ATIII activity levels in the peri-CPB period. Other sec-
ondary evaluations included the inhibition of thrombin activity, as
measured by changes in levels of fibrin monomer, the inhibition of
fibrinolysis as measured by changes in D-dimer levels, and the
changes in plasma ATIII activity levels at 2 time points: 30
minutes after initiation of CPB and before protamine
administration.
Study Medications
RhATIII, manufactured by GTC Biotherapeutics (Framingham,
Mass), was supplied in clear, glass, single-dose 20-mL vials and
was refrigerated at 2°C to 8°C until reconstitution. The institu-
tional research pharmacist at each study site prepared all study
materials and was the only person at the site who knew the
treatment assignment. Normal saline, indistinguishable from the
reconstituted rhATIII at the designated concentration, served as the
placebo control.
Statistics
It was anticipated that up to 500 patients would have to be
screened and consented to identify 52 eligible patients. With 24
patients in each group, there would be 80% power to detect a 40%
absolute reduction (65% vs 25%) in the proportion of patients
requiring FFP. A total of 52 randomized patients, 26 in each
treatment group, was recommended for the trial to account for a
dropout rate of approximately 10%. The primary end point of the
study was the comparison of the proportion of patients in each
treatment group requiring the infusion of FFP after administration
of study medication but before initiation of CPB.
The primary efficacy analysis, the difference between the pro-
portions of patients requiring FFP in each treatment group, was
assessed by using the Pearson 2 test or the Barnard unconditional
exact test, depending on the data distribution. Differences in the
treatment effect on the odds of requiring FFP were assessed by
using logistic regression. Odds ratios comparing treatment groups
and 95% confidence intervals were calculated if indicated.
The secondary efficacy end points, ACT values, and plasma AT
activity, were examined at 2 time points: 30 minutes after initiation
of CPB and before protamine administration. Differences between
the group means were assessed at each time point by analysis of
variance. Cohort differences in change from baseline (time 0) in
levels of fibrin monomer, D-dimer, and plasma ATIII at 30 min-
utes after CPB initiation and before protamine were assessed with
an analysis of variance model or rank sum test, depending on data
distribution. Two additional parameters, indicators of thrombin
activation that were recognized as useful but were evaluated after
completion of the study, were measured at baseline (time 0), at 30
minutes after initiation of CPB, and at the preprotamine time point
in retained plasma samples. These included prothrombin fragment
1.2 and thrombin-antithrombin complex. Although not prospec-
tively defined, evaluation of these parameters was performed under
blinded conditions.
The Journal of ThoraciThe significance of shifts in safety parameters was evaluated
within each group by the McNemar test for binary variables and
the generalized McNemar test for more than 2 categories. The
difference between proportions of patients experiencing other
safety-related events (ie, rehospitalization, incidence of red blood
cell transfusion, platelet transfusion, additional blood product
transfusion, duration of surgical intensive care unit stay, duration
of hospitalization, 30-day incidence of rehospitalization, myocar-
dial infarction, stroke, or death) were assessed by the Barnard
unconditional exact test.
Results
Across all of the study centers, the distribution of patients
randomized to receive rhATIII or placebo was well bal-
anced. Of the 493 patients who were originally screened,
183 passed the initial screening test and had HDR
(Medtronics) slopes of less than 80 seconds. Sixty-six of
these patients (66/493 [13%]) were found to be heparin
resistant (ACT  480 seconds after 400 U/kg heparin), and
52 were randomly assigned to receive rhATIII (n  28) or
placebo (n 24). Patient characteristics, including age, sex,
race, and weight, did not differ between groups.
In the intraoperative period, during which FFP adminis-
tration was guided by study protocol, 6 (21%) of 28 of
patients in the rhATIII group received FFP compared with
22 (92%) of 24 patients in the placebo group (P  .001).
This primary end point was similarly distributed across
study centers for both treatment groups. In the 24-hour
postoperative period, blood and blood component adminis-
tration was guided by clinician discretion. There was no
significant difference in the FFP, packed red blood cell, or
platelet administration between the 2 groups in the 24-hour
postoperative period. There was no significant difference
between the groups in 24-hour postoperative bleeding.
ATIII activity was low at baseline in both groups and not
significantly different in the 2 groups. In the rhATIII group,
ATIII activity increased to within the normal range during
CPB. In the placebo group, ATIII activity decreased even
lower than it had been at baseline during CPB (Figure 1).
There was a significant difference between the 2 groups
in D-dimer concentration toward the end of CPB (P  .05),
with patients in the rhATIII group showing less evidence of
fibrinolysis (ie, lower D-dimer levels). There was no signif-
icant difference between the 2 groups at any time point in
fibrin monomer concentration or in the change in fibrin
monomer concentration from baseline. The prothrombin
fragment 1.2 concentrations increased significantly from
baseline (1.1  0.5 nmol/L) in the placebo group at both
time points during CPB (2.2  2.0 and 3.9  2.8 nmol/L,
P  .01). In the rhATIII group, there was no significant
change in the prothrombin fragment 1.2 concentrations. The
thrombin-antithrombin concentrations increased signifi-
cantly in both groups during CPB (P  .001), and this was
more marked in the placebo group (Figure 2).
c and Cardiovascular Surgery ● Volume 130, Number 1 109
Cardiopulmonary Support and Physiology Avidan et al
CSPFigure 1. rhATIII activity for patients in each group at 3 time points around the CPB period. Time 0, Before
institution of CPB; 30 min on CPB, 30 minutes after institution of CPB; Preprotamine, CPB period just before
protamine administration. The normal range for plasma AT activity is 70% to 130%.Figure 2. Thrombin-antithrombin complex concentrations for patients in each group at 3 time points around the
CPB period. Time 0, Before institution of CPB; 30 min on CPB, 30 minutes after institution of CPB, Preprotamine, CPB
period just before protamine administration.
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PA total of 18 (64%) of 28 patients treated with rhATIII
required at least one additional heparin dose some time
between administration of study medication and heparin
reversal with protamine. Almost all of the placebo-treated
patients (23/24 [96%]) required at least one additional dose
of heparin during the same period. Thirteen placebo-treated
patients and 17 rhATIII-treated patients required only one
additional dose of heparin. Ten placebo-treated patients and
only 1 rhATIII-treated patient required between 2 and 4
additional doses of heparin.
The ACT was significantly increased in the rhATIII
group compared with that in the placebo group after rhATIII
administration and during CPB (P  .001, Figure 3).
There were no patient deaths among the 28 patients
randomized to be treated with rhATIII. The difference
between treatment groups in the incidence of patients
experiencing safety-related events (eg, volume of chest
tube drainage, incidence of red blood cell transfusion,
platelet transfusion, additional blood product transfusion,
duration of surgical intensive care unit stay, duration of
hospitalization, and 30-day incidence of rehospitaliza-
tion, myocardial infarction, stroke, or death) was as-
sessed. There was no significant difference in any of the
major or minor adverse events reported between the
treatment and placebo groups. The mean postoperative
bleeding in the placebo group was 83 mL/h compared
Figure 3. Activated clotting times for patients in eachwith 82 mL/h in the rhATIII group.
The Journal of ThoraciDiscussion
The most important implication of this study is that it
demonstrates that rhATIII effectively restores heparin re-
sponsiveness before CPB in the majority of heparin-resis-
tant patients without increasing the incidence of bleeding.
The primary end point of this randomized, double-blind,
placebo-controlled study was achieved. The proportion of
patients requiring administration of 2 units of FFP with the
intention of achieving therapeutic anticoagulation, defined
by an ACT of 480 seconds or longer, was significantly less
(P  .001) in the rhATIII-treated group (21%) than in the
placebo group (92%). There were 6 patients who received
rhATIII and FFP after heparin (400 U/kg) administration.
This suggests that some patients (21%) in the rhATIII group
had a heparin resistance mechanism other than ATIII
deficiency.9-12
The concept that ATIII deficiency is an important cause
of heparin resistance in patients undergoing cardiac surgery
was supported by the study data. Patients in the placebo
group had a mean baseline ATIII activity of 61% (normal,
70%-130%). Furthermore, CPB-associated hemodilution in-
duced a further decrease in ATIII activity to a mean of 42%
activity in placebo-treated patients. In this group ATIII
activity remained abnormally low throughout CPB. Impor-
tantly, despite the additional heparin the patients in the
placebo group received, the ACTs remained low during
p over the course of the study before and during CPB.grouCPB compared with those in patients in the rhATIII group
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CSP(Figure 3). Administering additional heparin is not without
potential complications, including increased bleeding and
heparin rebound in the postoperative period. Administration
of 75 U/kg rhATIII restored the mean plasma ATIII activity
to greater than 100% activity despite hemodilution during
CPB and maintained mean ATIII activity within normal
physiologic range throughout CPB. This finding supports
the chosen dose of rhATIII (75 U/kg). The large disparity in
maximum ATIII plasma activity levels between the 2
groups demonstrates that administration of 2 units of FFP is
not effective for normalizing plasma ATIII activity. Admin-
istration of rhATIII at a dose of 75 U/kg was well tolerated
by heparin-resistant patients undergoing CPB. There was no
difference in the incidence of serious adverse events or the
incidence of clinically significant abnormal laboratory pa-
rameters between the 2 treatment groups. Importantly,
rhATIII administration in this setting was not associated
with increased intraoperative or postoperative blood loss.
FFP was administered empirically to patients who were
bleeding postoperatively, including to patients who had
received rhATIII. This approach, however, has fallen out of
favor on the basis of studies that demonstrate that prophy-
lactic FFP13 and platelet14 administration do not decrease
bleeding. Postoperative transfusion of blood and blood
components was similar in the 2 groups.
During CPB, blood and the artificial surface of the by-
pass circuit come into contact, providing a powerful stim-
ulus to activate the hemostatic system. Subsequently, tissue
factor and tissue plasminogen activator are retransfused to
the patient through cardiotomy suction, resulting in sys-
temic activation of the hemostatic system.2 Without antico-
agulation, clots can form in the bypass circuit and might
result in circuit occlusion or intracardiac thrombosis.15 In
addition, with subtherapeutic anticoagulation, hemostatic
system activation through thrombin and plasmin results in
depletion of factors and platelets because of inadequate
suppression of a disseminated intravascular coagulation–
like consumptive state. To prevent these events, heparin is
used to promote the action of ATIII in the blood, thereby
reducing thrombin generation, thrombin activity, and fibrin
generation extracorporeally and systemically. Therefore,
heparin resistance might lead to inadequate anticoagulation
during CPB and potentially lead to an increase in bleeding,
thrombotic complications, or both.
Although gross clot formation in the extracorporeal cir-
cuit rarely occurs, activation of the hemostatic system still
has important clinical implications. CPB activation of the
hemostatic system has been implicated in the generation of
cerebral microemboli, one of the proposed causes of stroke,
and neurologic deficit often observed after CPB.16 Simi-
larly, intraoperative coronary,17 pulmonary intracardiac,18
and CPB circuit thromboses have all been described during
cardiac surgery. Postoperative bleeding might result from
112 The Journal of Thoracic and Cardiovascular Surgery ● Julyplatelet and labile coagulation factor consumption caused
by thrombin activity during CPB.2
Judging from surrogate markers, the results from this
study are strongly suggestive that there was less hemostatic
system activation in the group that received rhATIII. There
was less activation of markers of both thrombin (eg, pro-
thrombin fragments 1.2 and thrombin antithrombin com-
plexes) and fibrinolytic activity (eg, D-dimer). Heparin-
resistant patients might be at risk for the consequences of
inadequate anticoagulation during CPB. Previous studies
have demonstrated that more pronounced anticoagulation
with heparin can reduce transfusion requirements19 and
preserve the hemostatic system.20 Studies have demon-
strated that ATIII supplementation can attenuate thrombin
and fibrinolytic activity.7 This suppression of thrombin and
fibrinolytic activity, both of which usually increase during
CPB, might represent better inhibition of hemostatic acti-
vation than that achieved with heparin alone.7 The problem
with detecting rare clinical events is that large numbers of
patients are needed to detect these. For example, if giving
rhATIII would result in a decrease in thrombotic complica-
tions in heparin-resistant patients from 10% to 5%, 433
patients would be required in each group (power, 80%; P 
.05) to detect this. Assuming a 13% incidence of heparin
resistance, 6662 patients (866/6662 [13%]) would have to
be recruited to such a study. It is for this reason that we
looked at surrogate markers.
This is the second randomized, double-blind, placebo-
controlled trial that has demonstrated that rhATIII is effec-
tive in the management of heparin resistance in patients
undergoing cardiac surgery with CPB.21 There was a sug-
gestion in the other study that rhATIII might be associated
with increased postoperative bleeding.21 There was no in-
crease in postoperative bleeding with rhATIII in the present
study. Heparin resistance was caused by ATIII deficiency in
the majority of cases because the ACT was prolonged to the
therapeutic range (480 seconds) in 79% of patients after
rhATIII administration. Administration of 75 U/kg rhATIII
restored ATIII activity to within the normal range, which
led to improved heparin responsiveness, adequate anticoag-
ulation for CPB, and avoidance of FFP administration in the
majority of cases. In contrast, ATIII activity decreased
further from baseline in placebo-treated patients and re-
quired FFP treatment and additional heparin administration
to obtain adequate anticoagulation before CPB initiation.
Two units of FFP did not restore ATIII activity to the
normal range.
In summary, the present study demonstrated that 75 U/kg
rhATIII can be administered to heparin-resistant patients
undergoing CPB and effectively restores heparin respon-
siveness in the vast majority of cases. There was strong
evidence that rhATIII administration decreased hemostatic
system activation during CPB. In addition, this prospective
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Ptrial demonstrates that rhATIII administration for manage-
ment of heparin resistance might substantially reduce expo-
sure to FFP.
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